BioCentury
ARTICLE | Clinical News

AV-101: Phase II start

March 16, 2015 7:00 AM UTC

Next quarter, VistaGen said NIH’s National Institute of Mental Health (NIMH) will begin a double-blind, placebo-controlled, crossover, U.S. Phase II trial to evaluate 1,440 mg oral AV-101 once daily f...